OMass Therapeutics announces Collaboration and License Agreement for IBD with Genentech Worth $420 Million
On Sept. 2, 2025, OMass Therapeutics announces an exclusive collaboration and license agreement with Genentech, a member of…
On Sept. 2, 2025, OMass Therapeutics announces an exclusive collaboration and license agreement with Genentech, a member of…